Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded on 13th August 1996, Cyclacel is a biopharmaceutical company that designs and develops small-molecule
drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving
abnormal cell proliferation. The company's discovery engines integrate core cell cycle expertise with a large library of
proprietary gene-based targets, state-of-the-art molecular biology, RNAi functional genomics, computational chemistry
and biomarker technology to rapidly deliver new drug candidates.